Dishi Medical has recently announced the successful completion of nearly RMB 100 million in Series A funding, led by Pliner Capital, with participation from Shangcheng Capital, Jinhe Capital, and other notable investors. This substantial influx of capital will primarily be directed towards expediting the registration and clinical deployment of microsurgery robots, as well as the commercialization of ophthalmic surgery robots. Notably, Dishi Medical's ophthalmic surgery robot has successfully navigated the National Medical Products Administration (NMPA) audit and entered the "Green Channel" for expedited review of innovative medical devices, marking it as the first domestic ophthalmic surgery robot to achieve this milestone.

Furthermore, Dishi Medical's general microsurgery robot has distinguished itself by successfully performing multiple groundbreaking surgeries, which have significantly elevated the standards of surgical safety and precision. The company remains steadfast in its commitment to delivering high-precision, user-friendly solutions tailored to the needs of clinical surgeries.